临床荟萃
臨床薈萃
림상회췌
CLINICAL FOCUS
2015年
9期
1036-1038
,共3页
肝肿瘤%扶正固本%血管内皮生长因子%基质金属蛋白酶 9
肝腫瘤%扶正固本%血管內皮生長因子%基質金屬蛋白酶 9
간종류%부정고본%혈관내피생장인자%기질금속단백매 9
liver neoplasms%strenth resist consol constit%vascular endothelial growth factor%matrix metalloproteinase 9
目的：探讨扶正补虚方治疗原发性肝癌治疗效果及对患者免疫功能和血管生长因子的影响。方法将86例原发性肝癌患者采用随机数字表法分为观察组与对照组,对照组给予常规化疗方案,观察组在对照组基础上联合扶正补虚方治疗,记录两组疗效。结果观察组治疗总有效率为32.6%(14/43),对照组治疗总有效率为14.0%(6/43),差异有统计学意义(P <0.05)。观察组治疗后 CD3+ T(65.98±7.83),CD4+ T(41.02±5.27),CD8+ T (21.34±2.05),CD4+ T/CD8+ T(1.59±0.84)；对照组治疗后 CD3+ T(52.93±5.24),CD4+ T(31.89±4.11),CD8+T(34.85±4.59),CD4+ T/CD8+ T(1.03±0.45),差异有统计学意义(P <0.05)。观察组治疗后血管内皮生长因子(VEGF)(21.05±5.78)ng/L,基质蛋白酶9(MMP-9)(6.11±2.41)ng/L；对照组治疗后 VEGF(29.02±9.97)ng/L, MMP-9(9.63±4.01)ng/L,差异有统计学意义(P <0.05)。结论采用扶正补虚方可以提高原发性肝癌临床疗效,通过改善肝癌患者细胞免疫功能,抑制患者血清 VEGF 和 MMP-9浓度,值得在临床上推广应用。
目的：探討扶正補虛方治療原髮性肝癌治療效果及對患者免疫功能和血管生長因子的影響。方法將86例原髮性肝癌患者採用隨機數字錶法分為觀察組與對照組,對照組給予常規化療方案,觀察組在對照組基礎上聯閤扶正補虛方治療,記錄兩組療效。結果觀察組治療總有效率為32.6%(14/43),對照組治療總有效率為14.0%(6/43),差異有統計學意義(P <0.05)。觀察組治療後 CD3+ T(65.98±7.83),CD4+ T(41.02±5.27),CD8+ T (21.34±2.05),CD4+ T/CD8+ T(1.59±0.84)；對照組治療後 CD3+ T(52.93±5.24),CD4+ T(31.89±4.11),CD8+T(34.85±4.59),CD4+ T/CD8+ T(1.03±0.45),差異有統計學意義(P <0.05)。觀察組治療後血管內皮生長因子(VEGF)(21.05±5.78)ng/L,基質蛋白酶9(MMP-9)(6.11±2.41)ng/L；對照組治療後 VEGF(29.02±9.97)ng/L, MMP-9(9.63±4.01)ng/L,差異有統計學意義(P <0.05)。結論採用扶正補虛方可以提高原髮性肝癌臨床療效,通過改善肝癌患者細胞免疫功能,抑製患者血清 VEGF 和 MMP-9濃度,值得在臨床上推廣應用。
목적：탐토부정보허방치료원발성간암치료효과급대환자면역공능화혈관생장인자적영향。방법장86례원발성간암환자채용수궤수자표법분위관찰조여대조조,대조조급여상규화료방안,관찰조재대조조기출상연합부정보허방치료,기록량조료효。결과관찰조치료총유효솔위32.6%(14/43),대조조치료총유효솔위14.0%(6/43),차이유통계학의의(P <0.05)。관찰조치료후 CD3+ T(65.98±7.83),CD4+ T(41.02±5.27),CD8+ T (21.34±2.05),CD4+ T/CD8+ T(1.59±0.84)；대조조치료후 CD3+ T(52.93±5.24),CD4+ T(31.89±4.11),CD8+T(34.85±4.59),CD4+ T/CD8+ T(1.03±0.45),차이유통계학의의(P <0.05)。관찰조치료후혈관내피생장인자(VEGF)(21.05±5.78)ng/L,기질단백매9(MMP-9)(6.11±2.41)ng/L；대조조치료후 VEGF(29.02±9.97)ng/L, MMP-9(9.63±4.01)ng/L,차이유통계학의의(P <0.05)。결론채용부정보허방가이제고원발성간암림상료효,통과개선간암환자세포면역공능,억제환자혈청 VEGF 화 MMP-9농도,치득재림상상추엄응용。
Objective To explore the effect of Fuzhengbuxu decotionon on the immune function and vascular growth factors in patients with primary liver carcinoma.Methods According to random number table method,86 patients with primary werer carcinoma were divided into observation group and control group.Control group received conventional chemotherapy regimens, observation group got conventional chemotherapy regimens plus the Fuzhengbuxu decotion.Curative effects were observed between the two groups.Results Total effectiveness of treatment group was 32.6%(14/43),that of control group was 14.0%(6/43)(P <0.05).After treatment,CD3 + , CD4 + ,CD8 + ,CD4 +/CD8 + of oberservation group were respectively (65.98±7.83),(41.02±5.27),(21.34±2.05), (1.59±0.84);those of the control group were (52.93±5.24),(31.89±4.1 1),(34.85±4.59),(1.03 ±0.45)(P <0.05).After treatment,serum vascular endothelial growth factor(VEGF)and matrix metalloproteinases-9(MMP-9) of observation group were (21.05 ± 5.78 )ng/L and (6.1 1 ± 2.41 )ng/L respectively;VEGF and MMP-9 of the control group were (29.02 ± 9.97 )ng/L and (9.63 ± 4.01 )ng/L(P < 0.05 ).Conclusion Fuzhengbuxu decotion could improve the clinical efficacy of primary liver carcinoma,by improving cellular immune function and suppressing concentration of serumVEGF and MMP-9,the medicine deserves the clinical expansion application.
